In silico design Stable molecule Formulation development Market launch

FGF2 for stem cell cultivation

Product

  FGF2-STAB®
(patent WO2017089016A1)
 

Global distribution agreement

Global license agreement

FGF2 for cultured meat media

Product

  FGF2-STAB®
(patent WO2017089016A1)
  Distributors and licensing partners sought
FGF2 for cosmetics   FGF2-STAB®
(patent WO2017089016A1)
 

Licensing partners sought

Product development and testing finished (supported by OPPIK – Aplikace)

FGF2 for veterinary medicine   FGF2-STAB®
(patent WO2017089016A1)
  Licensing partners sought
FGF2 for wound healing   FGF2-STAB®
(patent WO2017089016A1)
 

Preclinical testing design (supported by Innovation Voucher)

Preclinical efficacy testing (supported by Innovation Voucher)

Licensing partners sought

FGF10 for cultivation media

Product

  FGF10-STAB®
(patent filed)
  Global distribution agreement
FGF10 for lung injury/disease treatment (ALI/ARDS)   FGF10-STAB®
(patent filed)
 

Preclinical testing stage

Licensing partners sought

FGF7 for cell cultivation media      

Test samples on request

Licensing partners sought

FGF18 for osteoarthritis treatment   FGF18-STAB
(patent granted)
 

Test samples on request

Licensing partners sought

FGF20 for neurodegenerative disease treatment (AD and PD)      

Test samples on request

Licensing partners sought

FGF21 for metabolic disease treatment (obesity and diabetes)      

Test samples on request

Licensing partners sought

Other FGFs for cell culture and medical use FGFx                            (3 new molecules)      

 

Our molecules are being developed with support of: